Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism

Bartsch, Christian; Bartsch, H.; Bellmann, O.; Lippert, T. H.

doi:10.1002/1097-0142(19910315)67:6<1681::aid-cncr2820670634>3.0.co;2-0

Cited by 54 publications

(27 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six epidemiologic studies have reported decreased melatonin levels in patients with breast cancer (68)(69)(70)(71)(72)(73), although in each of these studies, melatonin levels were measured after diagnosis, making it uncertain whether the disease itself and/or treatment might have affected melatonin levels among the cases. At least 4 studies have measured urinary melatonin levels in women before their development of breast cancer (74)(75)(76)(77).…”

Section: Discussionmentioning

confidence: 99%

Night Shift Work and Hormone Levels in Women

Davis

Mirick

Chen

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

105

View full text Add to dashboard Cite

Background: Night shift work may disrupt the normal nocturnal rise in melatonin, resulting in increased breast cancer risk, possibly through increased reproductive hormone levels. We investigated whether night shift work is associated with decreased levels of urinary 6-sulfatoxymelatonin, the primary metabolite of melatonin, and increased urinary reproductive hormone levels.Methods: Participants were 172 night shift and 151 day shift-working nurses, aged 20-49 years, with regular menstrual cycles. Urine samples were collected throughout work and sleep periods and assayed for 6-sulfatoxymelatonin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estrone conjugate (E1C).Results: 6-Sulfatoxymelatonin levels were 62% lower and FSH and LH were 62% and 58% higher, respectively, in night shift-working women during daytime sleep than in day shift-working women during nighttime sleep (P 0.0001). Nighttime sleep on off-nights was associated with 42% lower 6-sulfatoxymelatonin levels among the night shift workers, relative to the day shift workers (P < 0.0001); no significant differences in LH or FSH were observed. 6-Sulfatoxymelatonin levels during night work were approximately 69% lower and FSH and LH were 35% and 38% higher, compared with day shift workers during nighttime sleep. No differences in E1C levels between night and day shift workers were observed. Within night shift workers, 6-sulfatoxymelatonin levels were lower and reproductive hormone levels were higher during daytime sleep and nighttime work, relative to nighttime sleep (P < 0.05).Conclusions: These results indicate that night shift workers have substantially reduced 6-sulfatoxymelatonin levels during night work and daytime sleep and that levels remain low even when a night shift worker sleeps at night.Impact: Shift work could be an important risk factor for many other cancers in addition to breast cancer. MeSH Subject Headings: breast cancer, shift work, circadian rhythm, environmental carcinogens, estrogen, melatonin, 6-sulfatoxymelatonin, pineal. Cancer Epidemiol Biomarkers Prev; 21(4); 609-18. Ó2012 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

Night Shift Work and Hormone Levels in Women

Davis

Mirick

Chen

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

105

View full text Add to dashboard Cite

show abstract

“…In contrast, patients with secondary breast cancer showed nocturnal melatonin and aMT6s concentrations and amplitudes similar to benign breast disease [223] 8 young men, 7 elderly patients with benign prostatic hyperplasia and 9 patients of similar age with primary prostate cancer Serum and urine melatonin and aMT6s levels over 24 h…”

Section: Plasma Melatonin Levels Over 24 Hmentioning

confidence: 99%

Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance

Cardinali¹,

Escames²,

Acuña-Castroviejo³

et al. 2016

J Integr Oncol

View full text Add to dashboard Cite

“…The third study found no relationship between melatonin level and breast cancer risk (60); however, a primary concern with that study was the use of a 24-h urine sample to assess melatonin levels, which has several concerns as described by Hrushesky and Blask (61). There is evidence that melatonin levels are decreased in patients with breast cancer, although, in each of these studies, melatonin levels were measured after diagnosis; therefore, it is uncertain whether the disease itself and/or treatment might have affected melatonin levels among the cases (62)(63)(64)(65)(66)(67). Nighttime plasma melatonin levels have been reported to be lower in women with estrogen receptor-positive breast cancer than in estrogen receptornegative breast cancer, which in turn are lower than in healthy control women, and women with the lowest peak melatonin concentrations had tumors with the highest concentrations of estrogen receptors (66).…”

Section: Cancer Epidemiol Biomarkers Prev 2008;17(12) December 2008mentioning

confidence: 99%

Melatonin as a Biomarker of Circadian Dysregulation

Mirick

Davis

2008

Cancer Epidemiology, Biomarkers &Amp; Prevention

141

108

View full text Add to dashboard Cite

It would be most useful to identify a biomarker of circadian dysregulation that could be used in epidemiologic studies of the effects of circadian disruption in humans. An indicator of circulating melatonin level has been shown to be a good biomarker of circadian dysregulation and has been associated with nightshift work and exposure to light-at-night in both laboratorybased and field studies. Among other circadian markers (such as core body temperature), it remains comparatively robust in the presence of various external influences. It can be reliably measured directly and indirectly through its metabolites in urine, blood, and saliva. Urinary melatonin has been shown to be stable over time, making it useful in epidemiologic studies in which laboratory processing is not immediately available, as well as studies of cancer with long latency periods. Several studies have shown melatonin to be useful in measuring diurnal type, which is of increasing interest as it becomes more apparent that successful adaptation to shift work may be dependent on diurnal preference. (Cancer Epidemiol Biomarkers Prev 2008;17(12):3306 -13)

show abstract

Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism

Cited by 54 publications

References 12 publications

Night Shift Work and Hormone Levels in Women

Night Shift Work and Hormone Levels in Women

Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance

Melatonin as a Biomarker of Circadian Dysregulation

Contact Info

Product

Resources

About